You say that the conditions (of Rights Vesting) "align with the interests of shareholders".
I disagree.
The strike price of 15 cents per share (Class D) is way too low, since:
(a) many shareholders would have bought in at over 25 cents (Remember, a placement was made a year or so ago at 24 cents).
(b) 50% of the vesting is weighted towards Class D, rather than towards the much more beneficial (to shareholders) Class C which is allocated only 16.6%.
(c) If, and when, Class C is achieved, the share price will rocket upwards, probably to around one dollar. That is where the focus should be.
In this sense, the scheme stinks.
- Forums
- ASX - By Stock
- ETM
- Ann: Change of Director's Interest Notice x 4
Ann: Change of Director's Interest Notice x 4, page-15
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
TLX
Telix jumps 11.6% as US government indicates proposed medicare changes won't affect prostate cancer drug
RNU
Renascor wins a funding boost given it wants to produce a critical mineral – but $5M award pales in comparison to some
Add ETM (ASX) to my watchlist
(20min delay)
|
|||||
Last
2.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $29.49M |
Open | High | Low | Value | Volume |
2.1¢ | 2.1¢ | 2.0¢ | $47.47K | 2.326M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
9 | 3374763 | 1.9¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
2.2¢ | 536181 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
7 | 1294763 | 0.019 |
5 | 2040226 | 0.018 |
2 | 2176470 | 0.017 |
1 | 625000 | 0.016 |
1 | 42000 | 0.015 |
Price($) | Vol. | No. |
---|---|---|
0.022 | 536181 | 4 |
0.024 | 162542 | 2 |
0.025 | 120000 | 1 |
0.026 | 8000 | 1 |
0.028 | 72708 | 2 |
Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
Featured News
RNU
Renascor wins a funding boost given it wants to produce a critical mineral – but $5M award pales in comparison to some
TLX
Telix jumps 11.6% as US government indicates proposed medicare changes won't affect prostate cancer drug
ETM (ASX) Chart |